PAM
NMTR

Panagora Asset Management’s 9 Meters Biopharma NMTR Stock Holding History

Panagora Asset Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,793
Closed -$411K – 1756
2021
Q3 		$411K Buy
+15,793
New +$372K ﹤0.01% 1391

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Panagora Asset Management's NMTR Position: Q4 2021 in Review

Panagora Asset Management sold out of 9 Meters Biopharma (NMTR) in Q4 2021, closing a stake of 15,793 shares — an estimated $411K sold.

Panagora Asset Management first reported a position in NMTR in Q3 2021 and held it in 1 quarter. The position peaked at $411K in Q3 2021. 104 funds tracked by Wall St. Rank hold NMTR as of Q4 2021.

  • Panagora Asset Management reported no remaining 9 Meters Biopharma position as of Q4 2021 after selling out during the quarter.
  • Panagora Asset Management sold 15,793 9 Meters Biopharma shares in Q4 2021, an estimated $411K.
  • Panagora Asset Management first reported a position in 9 Meters Biopharma in Q3 2021 and held it in 1 quarter.
  • Panagora Asset Management's 9 Meters Biopharma position peaked at $411K in Q3 2021.
  • 104 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2021.

Based on Panagora Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.